MedTrace Logo

Predicting Cognitive Decline From Androgen Deprivation Therapy

NCT05820932 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 32

Last updated 2026-05-07

No results posted yet for this study

Summary

Androgen Deprivation Therapy (ADT) is associated with cognitive impairment and dementia in men with prostate cancer. Pre-clinical data suggest that ADT-induced hypogonadism leads to accumulation of beta-amyloid plaques in the hippocampus, a pathological hallmark of Alzheimer's Disease (AD). Neuroimaging Functional magnetic resonance imaging (fMRI) studies also demonstrate that ADT decreases metabolic activity in the parietal, occipital, and prefrontal cortices. Multiple prospective cohort and population-based clinical studies have been conducted to test the association between ADT and cognitive impairment and/or dementia.

Plasma biomarkers have been developed to predict brain amyloidosis, a key pathological feature of AD and a risk factor for developing dementia due to AD. The advantage of a blood-based assay is the lower cost, invasiveness, and time compared to cerebrospinal fluid (CSF) and Positron Emission Tomography (PET)-based biomarkers.

Conditions

Interventions

GENETIC

Blood-based assay

Blood samples will be collected

DIAGNOSTIC_TEST

Cognitive assessments

Cognitive assessments will be both participant- and partner-reported

OTHER

Quality of Life Surveys

Participant-reported Quality of Life Surveys

Sponsors & Collaborators

Principal Investigators

  • Daniel Kwon, MD · University of California, San Francisco

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-22
Primary Completion
2026-04-30
Completion
2026-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05820932 on ClinicalTrials.gov